OverviewSuggest Edit
BridgeBio is a a clinical-stage bioteccompany focused on discovering and developing drugs for patients with grievous genetic diseases. BridgeBio has built a portfolio of transformative drug programs that address rare diseases across oncology, cardiology, dermatology, neurology and endocrinology. The drugs are in various phases of development, from pre-clinical to late-stage.
| Type | Public | |
| Founded | 2014 | |
| HQ | Palo Alto, CA, US | Map |
| Website | bridgebio.com |
Recent NewsAll News
- BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
- BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
- BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting
- BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
Key People/Management at BridgeBio
Neil Kumar
Chief Executive Officer, Director
Charles Homcy
Chairman of Pharmaceuticals, Lead Director
Uma Sinha
Chief Scientific Officer
Brian C. Stephenson
Chief Financial Officer
Richard Scheller
Chairman of Research & Development, Director
Eric Aguiar
Director
BridgeBio Office Locations
BridgeBio has an office in Palo Alto
Palo Alto, CA, US (HQ)
421 Kipling St
BridgeBio Financials and Metrics
BridgeBio Revenue
BridgeBio's revenue was reported to be $8.25 m in FY, 2020
| USD | |
|---|---|
Revenue (FY, 2020) | 8.2m |
Net income (FY, 2020) | (505.5m) |
EBIT (FY, 2020) | (474.5m) |
Market capitalization (5-Mar-2021) | 9.3b |
Closing stock price (5-Mar-2021) | 62.2 |
Cash (31-Dec-2020) | 356.1m |
EV | 9.0b |
BridgeBio's current market capitalization is $9.3 b.
Annual
Annual
Annual
| USD | FY, 2017 |
|---|---|
Financial Leverage | -1.7 x |
BridgeBio Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Adrenas Therapeutics, Inc. | ||
| Aspa Therapeutics, Inc. | ||
| BridgeBio Services, Inc. | ||
| Calcilytix Therapeutics, Inc. | ||
| CoA Therapeutics, Inc. | ||
| Dermecular Therapeutics, Inc. | ||
| Eidos Therapeutics, Inc. | ||
| Ferro Therapeutics, Inc. | ||
| Fortify Therapeutics, Inc. | ||
| Molecular Skin Therapeutics, Inc. |
BridgeBio Cybersecurity Score
BridgeBio Online and Social Media Presence
BridgeBio's Trends
BridgeBio News and Updates
February 28, 2021
BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant mortality rate; median overall survival age is about four years
February 25, 2021
BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
–Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, a potential best-in-class therapy for patients with …
February 24, 2021
BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting
Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET
February 19, 2021
BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
SAN FRANCISCO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate ML Bio Solu…
February 11, 2021
BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock
PALO ALTO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P. The selling stockholder…
February 02, 2021
BridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations
PALO ALTO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Venthera, which is focused on developing new treatment options for patients with rare vascular anomalies, today announced that the first patient has been dosed in its Phase 1/2 clinical trial o…
BridgeBio Blogs
December 20, 2018
Sr. Manager/Associate Director, Drug Substance Development
The post Sr. Manager/Associate Director, Drug Substance Development appeared first on BridgeBio.
December 20, 2018
Sr. Manager/Associate Director, Analytical Development
The post Sr. Manager/Associate Director, Analytical Development appeared first on BridgeBio.
December 18, 2018
Director, Formulation Development
The post Director, Formulation Development appeared first on BridgeBio.
September 17, 2018
Business Operations Manager
The post Business Operations Manager appeared first on BridgeBio.
August 24, 2018
Director/Senior Director, CMC Project Management
The post Director/Senior Director, CMC Project Management appeared first on BridgeBio.
August 21, 2018
Preclinical Associate Scientist
The post Preclinical Associate Scientist appeared first on BridgeBio.
BridgeBio Frequently Asked Questions
When was BridgeBio founded?
BridgeBio was founded in 2014.
Who are BridgeBio key executives?
BridgeBio's key executives are Neil Kumar, Charles Homcy and Uma Sinha.
How many employees does BridgeBio have?
BridgeBio has 248 employees.
What is BridgeBio revenue?
Latest BridgeBio annual revenue is $8.2 m.
What is BridgeBio revenue per employee?
Latest BridgeBio revenue per employee is $33.3 k.
Who are BridgeBio competitors?
Competitors of BridgeBio include WuXi AppTec, Hutchison China Meditech and Novartis.
Where is BridgeBio headquarters?
BridgeBio headquarters is located at 421 Kipling St, Palo Alto.
Where are BridgeBio offices?
BridgeBio has an office in Palo Alto.
How many offices does BridgeBio have?
BridgeBio has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies